In an official announcement, the National Agency for Food and Drugs Administration and Control (NAFDAC) has issued a public advisory regarding a safety recall initiated by the Ministry of Health and Prevention (MOHAP) in Abu Dhabi, United Arab Emirates. The recall pertains to Growlyn Drops 50ml, a dietary supplement manufactured by Aeon Formulations Pvt. Ltd. in India.
According to the MOHAP Quality Control Laboratory’s analysis, the levels of Ethylene Glycol (EG) and Diethylene Glycol (DEG) in Growlyn Drops exceeded the prescribed limits. These substances, known for their toxic nature, pose a severe risk to consumers, particularly infants for whom the product is designed to boost immunity and support healthy growth and development.
### Product Information:
– **Product Name:** Growlyn Drops 50ml
– **Manufacturer:** Aeon Formulations Pvt Ltd, India
– **Batch No.:** ADGR 2201
– **Manufacturing Date:** March 2022

### Health Risks:
Diethylene glycol and ethylene glycol, when ingested, can be toxic and potentially fatal. Adverse effects include abdominal pain, vomiting, diarrhea, inability to pass urine, headache, altered mental state, and acute kidney injury, which may lead to fatality.
### NAFDAC’s Caution:
Although the product is not currently listed in the NAFDAC database, caution is advised for importers, distributors, retailers, and consumers. Maintaining vigilance within the supply chain is crucial to prevent the importation, distribution, sale, and use of substandard or contaminated syrups.
NAFDAC emphasizes the importance of sourcing all medical products from authorized and licensed suppliers. The authenticity and physical condition of these products should be carefully verified to ensure consumer safety.
### Action Steps:
– **Discontinuation:** Individuals in possession of Growlyn Drops 50ml are urged to discontinue the sale or use of the product and promptly submit their stock to the nearest NAFDAC office.
– **Medical Attention:** If the product has been used on a baby, or if any adverse reactions or events are observed, seeking immediate medical advice from a qualified healthcare professional is paramount.
### Reporting and Contact Information:
Healthcare professionals and consumers are encouraged to report any suspicions of substandard and falsified medicines to the nearest NAFDAC office. Reports can be made by contacting NAFDAC on 08001623322 or via email at sf.alert@nafdac.gov.ng.
Additionally, reporting adverse events or side effects related to medicinal product use is crucial. This can be done through the NAFDAC website, the Med-safety application, or via email at pharmacovigilance@nafdac.gov.ng.
### NAFDAC’s Emphasis on Collective Vigilance:
NAFDAC underscores the importance of collective vigilance and prompt reporting to safeguard public health. This proactive approach helps prevent the circulation of potentially harmful products in the market, demonstrating the agency’s commitment to ensuring the well-being of consumers.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate